2026
article
OpenAlex
Aykut Demir, Maximilian Mönnig, Nesrine Aroua, Eleni Besiridou et autres
Targeting metabolic dependencies of leukemic stem cells (LSC) may open avenues to improve outcomes of patients suffering from acute myeloid leukemia (AML). LSCs rely heavily on an active tricarboxylic acid (TCA) cycle and mitochondrial oxidative phosphorylation whereas healthy hematopoietic stem and progenitor …
de, gb, ch
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Niklas Kehl, Tim R. Wagner, Simon Steiger, Tamara Boschert et autres
T cell-mediated immune surveillance is critical for cancer control, yet its role in bone marrow malignancies remains poorly understood. Here, we integrate TCR profiling, HLA immunopeptidomics, and functional screening to characterize tumor-reactive T cells in the bone marrow of patients with multiple …
de, us, gb
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Yi Liu, Annika Lauk, David Sedloev, Josephine Brysting et autres
Abstract Cancer immunotherapy has witnessed remarkable advancements, particularly in the development of chimeric antigen receptor (CAR) T cell therapy. Here, we integrated single chain variable fragment (scFv) development with CAR T cell generation based on a newly developed scFv phagemid library. High‐throughput …
de, gb
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Magdalena Antes, Eleni Besiridou, Maximilian Mönnig, Sergi Beneyto Calabuig et autres
Background: Acute myeloid leukemia (AML) is an aggressive myeloid malignancy, which is characterized by substantial inter and intra-patient heterogeneity. While treatment regimens lead to remission in most patients, relapse rates are high and overall survival remains poor. Rare leukemic stem cells (LSCs), …
de, es
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Maximilian Mönnig, Magdalena Antes, Sergi Beneyto‐Calabuig, Dominik Vonficht et autres
Background: Despite improvements of therapy regimens for acute lymphoblastic leukemia (ALL), a significant number of patients experience relapse or do not respond to treatment, highlighting the need for continued research into the underlying mechanisms and the development of new treatments. It has …
de, es
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Aykut Demir, Alireza Pouya, Maximilian Mönnig, Gernot Poschet et autres
Background: Acute Myeloid Leukemia (AML) is an aggressive hematologic malignancy with poor overall survival. While classic chemotherapy and novel agents, such as Venetoclax, lead to remission in majority of patients, relapses driven by therapy-resistant leukemic stem cells (LSCs) are commonly observed. Eradication …
de, ch
(code pays fourni par la source)